Groundbreaking achievements in cystic fibrosis therapy honored
Prof. Marcus Mall is Global Winner 2022 in the Life Sciences category of the Falling Walls Foundation.
Prof. Marcus Mall is Global Winner 2022 in the Life Sciences category of the Falling Walls Foundation.
Earlier treatment means disease progression is likely to be significantly slowed.
Under the direction of the BREATH scientist Prof. Dr. Burkhard Tümmler, the second edition of the monograph „Mutation-specific therapies in cystic fibrosis“ has now been published.
With triple therapy, the lungs of cystic fibrosis patients are better ventilated down to their most minor ramifications.
Further funding of clinical studies by the DZL in 2022. Two studies were successful in this year's application round.
Scientists at the DZL and Charité have found that a new triple therapy improves treatment outcomes for a common form of cystic fibrosis.
DZL researchers have discovered how airway obstruction promotes inflammatory responses that are part of the disease picture in cystic fibrosis and chronic obstructive pulmonary disease (COPD).
The DZL Annual Report 2020 has been published in German and English and is now available from the Media Center.
Regular examination of the lungs using magnetic resonance imaging (MRI) can detect how lung disease develops in children with cystic fibrosis.
A clinical trial has shown that a triple combination therapy consisting of three known compounds is both safe and effective in cystic fibrosis patients with relatively rare disease-causing genetic defects.
Every year, DZL allocates part of its budget to innovative clinical trials that are based on initiatives by DZL scientists (Investigator Initiated Trials). Four more trials, which will be described more specifically hereinafter, will be...
A team led by DZL researcher Prof. Burkhard Tümmler has studied the composition of the lung flora in infants and young children with and cystic fibrosis and discovered the development of a healthy lower airway...
